Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore (Nasdaq: IMCR) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunocore (Nasdaq: IMCR) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss results and provide a business and portfolio update.
Investors can access the live audio webcast via the 'Events' page in the Investors section at www.immunocore.com; a replay will be available for a limited time.
Details
News Market Reaction – IMCR
On Feb 18, the day this news came out, IMCR closed 0.40% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Earnings release date
- February 25, 2026
- Q4 and full-year 2025 financial results
- Fiscal year-end
- December 31, 2025
- Period covered by upcoming results
- Conference call time EST
- 8:00 a.m. EST
- Start time of earnings call
- Conference call time GMT
- 1:00 p.m. GMT
- Start time of earnings call
- Domestic dial-in
- 877-405-1239
- U.S. toll-free conference line
- International dial-in
- +1 201-389-0851
- International conference line
Historical Context
-
Head of R&D departure with internal promotions and streamlined R&D structure.
-
Outlined 2026 strategic priorities and cash of about $864M with slight price dip.
-
Announced presentations at two November 2025 investor conferences with webcasts.
-
Phase 1 hepatitis B data showing manageable safety and pharmacodynamic activity.
-
Q3 2025 results with higher KIMMTRAK sales and near breakeven net income.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026.
Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio update.
Audio Webcast
The call will be webcast live and can be accessed by visiting ‘Events’, under ‘Events and Presentations’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay will also be made available for a limited time.
Conference Call Details:
Domestic (toll-free): 877-405-1239
International (toll): +1 201-389-0851
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Morse
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.